MX355501B - Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. - Google Patents

Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.

Info

Publication number
MX355501B
MX355501B MX2013003470A MX2013003470A MX355501B MX 355501 B MX355501 B MX 355501B MX 2013003470 A MX2013003470 A MX 2013003470A MX 2013003470 A MX2013003470 A MX 2013003470A MX 355501 B MX355501 B MX 355501B
Authority
MX
Mexico
Prior art keywords
methods
same
made therefrom
consensus antigen
antigen constructs
Prior art date
Application number
MX2013003470A
Other languages
English (en)
Other versions
MX2013003470A (es
Inventor
B Weiner David
Yan Jian
Y Sardesai Niranjan
Ferraro Bernadette
Original Assignee
Inovio Pharmaceuticals Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc Star filed Critical Inovio Pharmaceuticals Inc Star
Publication of MX2013003470A publication Critical patent/MX2013003470A/es
Publication of MX355501B publication Critical patent/MX355501B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Body Structure For Vehicles (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a secuencias estructura de amonoácidos de proteínas P. falciparum (p.f.) y sus secuencias de codificación, así como estructuras de expresión que expresan las secuencias. También se proporcionan en la presente los métodos para generar una respuesta inmunitaria contra la P. falciparum utilizando las estructuras de expresión proporcionados en la presente.
MX2013003470A 2010-09-27 2011-09-27 Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria. MX355501B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38697310P 2010-09-27 2010-09-27
PCT/US2011/053541 WO2012047679A2 (en) 2010-09-27 2011-09-27 Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria

Publications (2)

Publication Number Publication Date
MX2013003470A MX2013003470A (es) 2013-08-01
MX355501B true MX355501B (es) 2018-04-20

Family

ID=45928328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003470A MX355501B (es) 2010-09-27 2011-09-27 Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.

Country Status (10)

Country Link
US (1) US10799572B2 (es)
EP (1) EP2621540A4 (es)
JP (1) JP6293485B2 (es)
KR (2) KR101891195B1 (es)
CN (2) CN103354750A (es)
AU (1) AU2011312465B2 (es)
BR (1) BR112013007051A2 (es)
CA (1) CA2812789A1 (es)
MX (1) MX355501B (es)
WO (1) WO2012047679A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796147A1 (en) * 2013-04-24 2014-10-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel vaccines against apicomplexan pathoges
EP2923709A1 (en) * 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
EP2992895A1 (en) * 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
CN105628928A (zh) * 2014-11-11 2016-06-01 深圳国际旅行卫生保健中心 可用于辅助诊断疟疾的试剂盒
US11179458B2 (en) * 2015-01-23 2021-11-23 The Trustees Of The University Of Pennsylvania Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
WO2018085444A1 (en) * 2016-11-01 2018-05-11 Washington University COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF
US20190076460A1 (en) * 2017-02-22 2019-03-14 Enyu Ding An mRNA cancer vaccine encoding human GM-CSF fused to multiple tandem epitopes
CN109125740B (zh) * 2017-06-28 2022-04-05 成都威斯克生物医药有限公司 一种新型的肿瘤疫苗及其用途
KR102169664B1 (ko) * 2019-02-26 2020-10-23 원광대학교산학협력단 열대열말라리아원충 유래의 EF-1α 재조합 단백질을 유효성분으로 포함하는 말라리아 예방용 백신 조성물
WO2022204597A1 (en) * 2021-03-26 2022-09-29 David Weiner Dna encoded nanoparticle vaccine against human papillomavirus, and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
WO1994016737A1 (en) 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
SG156535A1 (en) * 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
DK1628749T3 (da) 2003-05-30 2019-09-16 Vgxi Inc Anordninger og fremgangsmåder til biomateriel produktion
WO2005012528A1 (fr) 2003-08-01 2005-02-10 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Methode de preparation d'un vaccin a partir d'un gene chimere a epitopes
US8168166B2 (en) * 2003-12-19 2012-05-01 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
JP2009505680A (ja) * 2005-08-31 2009-02-12 ジェンベク、インコーポレイティッド アデノウイルスベクターに基づくマラリアワクチン
KR20100068390A (ko) * 2007-08-13 2010-06-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CA2720168C (en) * 2008-04-04 2024-04-30 David B. Weiner Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
US9120868B2 (en) * 2008-11-25 2015-09-01 The United States of America as Represented by the Secratary of the Army Recombinantly expressed Plasmodium CelTOS antigen and methods of use thereof
US20110229514A1 (en) * 2009-03-16 2011-09-22 Denise Doolan Vaccine and immunization method using plasmodium antigen 2

Also Published As

Publication number Publication date
CA2812789A1 (en) 2012-04-12
JP6293485B2 (ja) 2018-03-14
US10799572B2 (en) 2020-10-13
KR20130138790A (ko) 2013-12-19
CN110195069A (zh) 2019-09-03
KR20180096814A (ko) 2018-08-29
BR112013007051A2 (pt) 2019-07-02
JP2013543721A (ja) 2013-12-09
CN103354750A (zh) 2013-10-16
MX2013003470A (es) 2013-08-01
EP2621540A2 (en) 2013-08-07
AU2011312465A1 (en) 2013-05-02
EP2621540A4 (en) 2014-08-27
WO2012047679A2 (en) 2012-04-12
KR101891195B1 (ko) 2018-08-24
WO2012047679A3 (en) 2012-06-14
WO2012047679A8 (en) 2012-08-16
US20130273112A1 (en) 2013-10-17
AU2011312465B2 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
MX355501B (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
MX2013008836A (es) Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso.
MX2021015971A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX2018008135A (es) Moleculas de acido nucleico de influenza y vacunas elaboradas a partir de las mismas.
JOP20200091A1 (ar) جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
IN2012DN00650A (es)
MY180109A (en) Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
MX2023009421A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
EA201290675A1 (ru) Вакцинные векторы и способы усиления иммунных ответов
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX363149B (es) Vacunas de nucleoproteina de la influenza.
MX2017016501A (es) Aminopeptidasas para hidrolizados de proteinas.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
DK201370413A (en) Salmonid alphavirus protein e2
MX2018014253A (es) Inmunógenos de malaria sintéticos, combinaciones de estos y su uso para prevenir y tratar infecciones de malaria.
PL391384A1 (pl) Kompleks rybosomalnych białek P z zarodźca malarii Plasmodium falciparum jako antygen patogenu malarii oraz sposób otrzymania tego antygenu i kaseta ekspresyjna, zwłaszcza do tego sposobu
WO2012158639A3 (en) Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
TN2010000332A1 (en) Recombinant influenza virus-like particles (vlps)produced in transgenic plants expressing hemagglutinin

Legal Events

Date Code Title Description
FG Grant or registration